Hikma US unit launches anti-depression tablets
Hikma Pharmaceuticals said its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. had launched its anti-depression tablets Pristiq (Desvenlafaxine Succinate).
FTSE 100
8,280.63
16:49 04/10/24
n/a
n/a
FTSE 350
4,570.17
17:14 04/10/24
n/a
n/a
FTSE All-Share
4,527.24
16:54 04/10/24
n/a
n/a
Hikma Pharmaceuticals
1,904.00p
16:44 04/10/24
-0.05%
-1.00p
Pharmaceuticals & Biotechnology
22,108.24
17:14 04/10/24
-1.30%
-291.15
Desvenlafaxine Succinate tablets are in a class of medications called selective serotonin and norepinephrine reuptake inhibitors, Hikma said on Friday.
US sales of Desvenlafaxine Succinate ER Tablets in 50 mg and 100 mg strengths were approximately $853m in the 12 months ending January 2017, according to health information group IMS.